These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 20575623

  • 1. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
    Hess DC, Fagan SC.
    Pharmacotherapy; 2010 Jul; 30(7 Pt 2):55S-61S. PubMed ID: 20575623
    [Abstract] [Full Text] [Related]

  • 2. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
    Hess DC, Fagan SC.
    Rev Neurol Dis; 2010 Jul; 7 Suppl 1(0 1):S7-13. PubMed ID: 20410869
    [Abstract] [Full Text] [Related]

  • 3. Extension of the thrombolytic time window with minocycline in experimental stroke.
    Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH.
    Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
    [Abstract] [Full Text] [Related]

  • 4. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
    Fan X, Lo EH, Wang X.
    Stroke; 2013 Mar; 44(3):745-52. PubMed ID: 23422086
    [Abstract] [Full Text] [Related]

  • 5. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
    Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, Waller JL, Fagan SC.
    Stroke; 2009 Sep; 40(9):3028-33. PubMed ID: 19628804
    [Abstract] [Full Text] [Related]

  • 6. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W, Hendren J, Qin XJ, Liu KJ.
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [Abstract] [Full Text] [Related]

  • 7. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
    Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV.
    Stroke; 2013 Dec; 44(12):3529-36. PubMed ID: 24159062
    [Abstract] [Full Text] [Related]

  • 8. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA, Starr JA.
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [Abstract] [Full Text] [Related]

  • 9. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S, Deguchi K, Morimoto N, Kurata T, Yamashita T, Ikeda Y, Narai H, Manabe Y, Takao Y, Kawada S, Kashihara K, Takehisa Y, Inoue S, Kiriyama H, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [Abstract] [Full Text] [Related]

  • 10. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke.
    Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, Pettigrew LC, Clark WM, Fagan SC.
    Stroke; 2011 Sep; 42(9):2633-5. PubMed ID: 21737808
    [Abstract] [Full Text] [Related]

  • 11. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
    Jin R, Xiao AY, Liu S, Wang M, Li G.
    Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
    [Abstract] [Full Text] [Related]

  • 12. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J.
    Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
    [Abstract] [Full Text] [Related]

  • 13. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study.
    Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC.
    Stroke; 2010 Oct; 41(10):2283-7. PubMed ID: 20705929
    [Abstract] [Full Text] [Related]

  • 14. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.
    Neurology; 2006 May 23; 66(10):1550-5. PubMed ID: 16717217
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.
    Lapchak PA.
    Brain Res; 2010 Jan 14; 1309():136-45. PubMed ID: 19891959
    [Abstract] [Full Text] [Related]

  • 16. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH, Kim BJ, Han MK, Park TH, Lee KB, Lee BC, Yu KH, Oh MS, Cha JK, Kim DH, Nah HW, Lee J, Lee SJ, Ko Y, Kim JG, Park JM, Kang K, Cho YJ, Hong KS, Choi JC, Kim JT, Choi K, Kim DE, Ryu WS, Kim WJ, Shin DI, Yeo M, Lee J, Lee JS, Gorelick PB, Bae HJ.
    Int J Stroke; 2016 Oct 14; 11(7):783-90. PubMed ID: 27312681
    [Abstract] [Full Text] [Related]

  • 17. The neurovascular unit and combination treatment strategies for stroke.
    Zhang L, Zhang ZG, Chopp M.
    Trends Pharmacol Sci; 2012 Aug 14; 33(8):415-22. PubMed ID: 22595494
    [Abstract] [Full Text] [Related]

  • 18. Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.
    David HN, Haelewyn B, Risso JJ, Colloc'h N, Abraini JH.
    J Cereb Blood Flow Metab; 2010 Apr 14; 30(4):718-28. PubMed ID: 20087367
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravenous thrombolysis for acute ischemic stroke in Asia.
    Sharma VK, Ng KW, Venketasubramanian N, Teoh HL, Chan BP.
    Expert Rev Neurother; 2012 Feb 14; 12(2):209-17. PubMed ID: 22288676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.